Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)
Zhengyang Yang(Capital Medical University), Zhongtao Zhang(Capital Medical University), Zhigang Bai(Capital Medical University), Jiagang Han(Capital Medical University), Wei Deng(Capital Medical University), Yi Sun(Tianjin People's Hospital), Jiale Gao(Capital Medical University), Xiao Zhang(Capital Medical University), Gang Liu(Tianjin Medical University General Hospital), Ang Li(University of Liverpool), Jie Zhang(Tongji University), Guangyong Chen(Wenzhou Medical University), Yishan Liu(Capital Medical University), Qi Wei(Tongji Hospital), Dalu Kong(Tianjin Medical University Cancer Institute and Hospital), Yongbo An(Capital Medical University), Hongwei Yao(Capital Medical University)
Cited by 26
Related Papers
Identification of Suitable Reference Genes for qPCR Analysis of Serum microRNA in Gastric Cancer Patients
|Digestive Diseases and Sciences|2011|269
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade
|Cancer Discovery|2020|143
Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity
|Nature Immunology|2019|121
Self-generating oxygen enhanced mitochondrion-targeted photodynamic therapy for tumor treatment with hypoxia scavenging
|Theranostics|2019|107
Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
|Bioscience Reports|2018|80